WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525218
CAS#: 892664-04-9
Description: GSK-269984A is a novel EP1 receptor antagonist.
Hodoodo Cat#: H525218
Name: GSK-269984A
CAS#: 892664-04-9
Chemical Formula: C20H13Cl2FNNaO3
Exact Mass: 0.00
Molecular Weight: 428.220
Elemental Analysis: C, 56.10; H, 3.06; Cl, 16.56; F, 4.44; N, 3.27; Na, 5.37; O, 11.21
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: GSK-269984A; GSK269984A; GSK 269984A;
IUPAC/Chemical Name: 2-Pyridinecarboxylic acid, 6-((5-chloro-2-((4-chloro-2-fluorophenyl)methoxy)phenyl)methyl)-, sodium salt
InChi Key: ROPHIKMBWGQPQO-UHFFFAOYSA-M
InChi Code: InChI=1S/C20H14Cl2FNO3.Na/c21-14-6-7-19(27-11-12-4-5-15(22)10-17(12)23)13(8-14)9-16-2-1-3-18(24-16)20(25)26;/h1-8,10H,9,11H2,(H,25,26);/q;+1/p-1
SMILES Code: O=C(C1=NC(CC2=CC(Cl)=CC=C2OCC3=CC=C(Cl)C=C3F)=CC=C1)[O-].[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 428.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Ostenfeld T, Beaumont C, Bullman J, Beaumont M, Jeffrey P. Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A. Br J Clin Pharmacol. 2012 Dec;74(6):1033-44. doi: 10.1111/j.1365-2125.2012.04296.x. PubMed PMID: 22497298; PubMed Central PMCID: PMC3522817.
2: Hall A, Billinton A, Brown SH, Chowdhury A, Clayton NM, Giblin GM, Gibson M, Goldsmith PA, Hurst DN, Naylor A, Peet CF, Scoccitti T, Wilson AW, Winchester W. Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecar boxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain. Bioorg Med Chem Lett. 2009 May 1;19(9):2599-603. doi: 10.1016/j.bmcl.2009.02.112. Epub 2009 Mar 3. PubMed PMID: 19332369.